(Q51782637)

12 April 2018

title

Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma. (English)

1 reference

12 April 2018

1 reference

8

1 reference

12 April 2018

Marina Konopleva

3

Marina Konopleva

1 reference

12 April 2018

6

Michael Andreeff

1 reference

12 April 2018

1

Yoko Tabe

1 reference

12 April 2018

Linhua Jin

2

Linhua Jin

1 reference

12 April 2018

Masato Shikami

4

Masato Shikami

1 reference

12 April 2018

Shinya Kimura

5

Shinya Kimura

1 reference

12 April 2018

author name string

Mark Raffeld

7

1 reference

12 April 2018

publication date

19 September 2013

1 reference

12 April 2018

published in

Acta Haematologica

1 reference

12 April 2018

volume

131

1 reference

12 April 2018

issue

1

1 reference

12 April 2018

page(s)

59-69

1 reference

12 April 2018

Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma

cites work

1 reference

12 December 2020

Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice

1 reference

12 December 2020

B cell receptor signaling: picky about PI3Ks

1 reference

12 December 2020

Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519).

1 reference

12 December 2020

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

1 reference

12 December 2020

The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways

1 reference

12 December 2020

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

1 reference

12 December 2020

Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex.

1 reference

12 December 2020

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

12 December 2020

Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis

1 reference

12 December 2020

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

1 reference

12 December 2020

PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?

1 reference

12 December 2020

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

1 reference

12 December 2020

Advances in development of phosphatidylinositol 3-kinase inhibitors

1 reference

12 December 2020

Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells

1 reference

12 December 2020

Recognizing and exploiting differences between RNAi and small-molecule inhibitors

1 reference

12 December 2020

The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.

1 reference

12 December 2020

Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.

1 reference

12 December 2020

Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis

1 reference

12 December 2020

Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement

1 reference

12 December 2020

Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma

1 reference

12 December 2020

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

1 reference

12 December 2020

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

12 December 2020

In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).

1 reference

12 December 2020

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

1 reference

12 December 2020

Phosphatidylinositol-3-OH kinase as a direct target of Ras

1 reference

12 December 2020

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

1 reference

12 December 2020

p110δ, a novel phosphoinositide 3-kinase in leukocytes

1 reference

12 December 2020

Establishment and characterization of a mantle cell lymphoma cell line

1 reference

12 December 2020

PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival

1 reference

12 December 2020

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

1 reference

12 December 2020

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

1 reference

12 December 2020

Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach

1 reference

12 December 2020

Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

1 reference

12 December 2020

Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene

1 reference

12 December 2020

Identifiers

DOI

10.1159/000353164

1 reference

12 April 2018

1 reference

12 April 2018